poster

Familiarity With Psychiatric Pharmacogenomic Testing in Physicians and Advanced Practice Providers: Educational Opportunities

This survey of 305 U.S. providers identified current pharmacogenomic testing trends and learning opportunities among MDs/DOs and advanced practice providers. Most respondents were unfamil...

10/26/2023

From Relief to Aggravation: The Intriguing Tinnitus-Opioid Withdrawal Paradox

This case report documents a patient who experienced persistent tinnitus for years after stopping heroin abuse. Tinnitus was temporarily relieved by heroin or morphine administration, wit...

10/26/2023

Growth Trajectories of Youth with Attention-Deficit/Hyperactivity Disorder Treated with Delayed-Release/Extended-Release Methylphenidate: A Pilot Database Analysis of Real-World Data

DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...

10/26/2023

Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to Selective Serotonin Reuptake Inhibitors: The VIVRE Study

This study assessed the efficacy of vortioxetine versus desvenlafaxine in patients with MDD experiencing partial response to treatment with an SSRI. Vortioxetine was noninferior to desven...

10/26/2023

Healthcare Resource Use and Cost Associated with Negative Symptoms of Schizophrenia

Information is sparse on the burden of healthcare resource utilization (HCRU) and costs among patients with negative symptoms of schizophrenia (NSS). Using a retrospective longitudinal ob...

10/26/2023

Equivalent Antidepressant Outcomes with Esketamine in TMS Non-Responders

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...

10/26/2023

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

10/26/2023

Efficacy of Brexpiprazole in Patients With Agitation Associated With Alzheimer’s Dementia Analyzed by Presence or Absence of Psychosis: a Pooled Analysis

This post hoc analysis explored the efficacy of brexpiprazole 2 or 3 mg/day in patients with agitation associated with Alzheimer’s dementia, based on presence or absence of psychosis at b...

10/26/2023

Efficacy of Fremanezumab in Reducing Depression in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine. In patients with migraine and major depressive disorder, treatment with fremanezumab was associated with significant reduct...

10/26/2023

Efficacy of Long-acting Injectable Risperidone in Acute and Stable Patients with Schizophrenia: Prior Anti-Psychotic Use, and Relapse

Adult patients with acute or stable schizophrenia received RBP-7000 (a once-monthly subcutaneous extended-release risperidone formulation) in two Phase III studies (8-week inpatient doubl...

10/26/2023

Tracks

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products